MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025

Reuters

10/20

MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025

MetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576517338"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576517338\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576517338?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576517338","market":"nz","top_or_hot":-1,"title":"MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-20 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL8PNqyk:1","article_id":"2576517338","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576517338","pubTimestamp":1760963488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor  and glucagon receptor . The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MTVA":"MetaVia Inc"},"translate_title":"MetaVia在2025年肥胖周上展示了有希望的DA-1726 1期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"MetaVia Showcases Promising DA-1726 Phase 1 Data at ObesityWeek 2025\n    \n\nMetaVia Inc., a clinical-stage biotechnology company, announced that two abstracts featuring data on its investigational drug DA-1726 have been accepted for poster presentations at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. DA-1726 is a novel dual oxyntomodulin analog agonist targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The presentations will include results from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of DA-1726, as well as an overview of its potential as a therapy for obesity and related metabolic disorders. Both posters are set to be presented on November 4, 2025. Copies of the posters will be made available on the MetaVia website following the presentations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01238) on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}